Ovarian surface epithelium: Biology, endocrinology, and pathology

Endocrine Reviews

Volumn 22, Issue 2, 2001, Pages 255-288

  Auersperg, Nelly ^a   Wong, Alice S T ^a   Choi, Kyung Chul ^a   Kang, Sung Keun ^a   Leung, Peter C K ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR; HORMONE;

ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; CELL GROWTH; EMBRYO DEVELOPMENT; EPITHELIUM; HISTOPATHOLOGY; HUMAN; OVARY CARCINOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADULT; CELLS, CULTURED; EPITHELIUM; FEMALE; HUMANS; OVARIAN NEOPLASMS; OVARY;

EID: 0035008525     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.22.2.255     Document Type: Article

References (450)

1. 1. Nicosia SV, Saunders BO, Acevedo-Duncan ME, Setrakian S, Degregorio R 1991 Biopathology of ovarian mesothelium. In: Familiari G, Makabe S, Motta PM (eds) Ultrastructure of the Ovary. Kluwer Academic Publishers, Boston, MA, pp 287-310
2. 2. Nicosia SV, Ku Ni Ni K, Oliveros-Saunders B, Giacomini G, Pierre E, Mayer J, Nicosia RF 1997 Ovarian mesothelium (surface epithelium) in normal, pathological and experimental conditions In: Motta PM (ed) Recent Advances in Microscopy of Cells, Tissues and Organs. Antonio Delfino Editore, Rome, pp 509-517
3. 3. Bast Jr RC, Xu F, Yu Y, Fang XJ, Wiener J, Mills GB 1998 Overview: the molecular biology of ovarian cancer. In: Sharp F, Backett T, Berek T, Bast R (eds) Ovarian Cancer. Isis Medical Media Publishers, Oxford, UK, vol 5:87-97
4. 4. Van Blerkom J, Motta PM (eds) 1979 The ovary prior to ovulation. In: The Cellular Basis of Mammalian Reproduction. Urban & Scharzenberg, Baltimore, pp 5-51
5. 5. Nicosia SV, Johnson JH 1984 Surface morphology of ovarian mesothelium (surface epithelium) and of other pelvic and extrapelvic mesothelial sites in the rabbit. Int J Gynecol Pathol 3:249-260
6. 6. Nicosia SV, Nicosia RF 1988 Neoplasms of the ovarian mesothelium. In: Azar HA (ed) Path of Human Neoplasms. Raven Press, New York, pp 435-486
7. 7. Herbst AL 1994 The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am J Obstet Gynecol 170:1099-1105
8. 8. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC 1998 The biology of ovarian cancer. Semin Oncol 25:281-304
9. 9. Dubeau L 1999 The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol 72:437-442
10. 10. Fredrickson TN 1987 Ovarian tumors of the hen. Environ Health Perspect 73:35-51
11. 11. Adams AT, Auersperg N 1981 Transformation of cultured rat ovarian surface epithelial cells by Kirsten murine sarcoma virus. Cancer Res 41:2063-2072
12. 12. Adams AT, Auersperg N 1983 Autoradiographic investigation of estrogen binding in cultured rat ovarian surface epithelial cells. J Histochem Cytochem 31:1321-1325
13. 13. Hamilton TC, Henderson WT, Eaton C 1980 Isolation and growth of the rat ovarian germinal epithelium. In: Richards RJ, Rajan KT (eds) Tissue Culture in Medical Research. Proceedings of the Second International Symposium. Pergamon Press, New York, vol II
14. 14. Nicosia SV, Narconis RJ, Saunders BO 1989 Regulation and temporal sequence of surface epithelium morphogenesis in the postovulatory rabbit ovary. In: Developments in Ultrastructure of Reproduction. Alan R Liss, Inc., New York, pp 111-119
15. 15. Auersperg N, Siemens CH, Myrdal SE 1984 Human ovarian surface epithelium in primary culture. In Vitro 20:743-755
16. 16. Siemens CH, Auersperg N 1988 Serial propagation of human ovarian surface epithelium in tissue culture. J Cell Physiol 134:347-356
17. 17. Auersperg N, Pan J, Grove BD, Peterson T, Fisher J, Maines-Bandiera S, Somasiri A, Roskelley CD 1999 E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci USA 96:6249-6254
18. 18. Ong A, Maines-Bandiera SL, Roskelley CD, Auersperg N 2000 An ovarian adenocarcinoma line derived from SV40/E-cadherin transfected normal human ovarian surface epithelium. Int J Cancer 85:430-437
19. 19. Jacobs I, Bast Jr RC 1989 The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 4:1-12
20. 20. Kabawat SE, Bast Jr RC, Bhan AK, Welch WR, Knapp RC, Colvin RB 1983 Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC-425. Int J Gynecol Pathol 2:275-85
21. 21. Byskov AR, Skakkebaek NE, Stafanger G, Peters H 1977 Influence of ovarian surface epithelium and rete ovarii on follicle formation. J Anat 123:77-86
22. 22. Stein LE, Anderson CH 1979 A qualitative and quantitative study of rete ovarii development in the fetal rat: correlation with the onset of meiosis and follicle cell appearance. Anat Rec 193:197-212
23. 23. Yoshinaga K, Hess DL, Hendrickx AG, Zamboni L 1988 The development of the sexually indifferent gonad in the prosimian, Galago crassicaudatus crassicaudatus. Am J Anat 181:89-105
24. 24. Hirshfield AN 1991 Development of follicles in the mammalian ovary. Int Rev Cytol 124:43-101
25. 25. Pan J, Auersperg N 1997 Spatiotemporal changes in cytokeratin expression. I. The neonatal rat ovary. Biochem Cell Biol 76:27-35
26. 26. Blaustein A, Lee H 1979 Surface cells of the ovary and pelvic peritoneum: a histochemical and ultrastructure comparison. Gynecol Oncol 8:34-43
27. 27. Auersperg N, Maines-Bandiera SL, Dyck HG, Kruk PA 1994 Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Invest 71: 510-518
28. 28. Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO 1998 Selection of tumor antigens as targets for immune attack using immunohistochemistry; protein antigens. Clin Cancer Res 4:2669-2676
29. 29. Kruk PA, Uitto VJ, Firth JD, Dedhar S, Auersperg N 1994 Reciprocal interactions between human ovarian surface epithelial cells and adjacent extracellular matrix. Exp Cell Res 215:97-108
30. 30. Cruet S, Salamanca C, Staedel C, Auersperg N 1999 αvβ3/Vitronectin expression by normal ovarian surface epithelial cells: role in cell adhesion and cell proliferation. Gynecol Oncol 75:254-260
31. 31. Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brannstrom M, Janson P-O, Enerback S, Hedin L 1997 E-cadherin expression in human epithelial ovarian cancer and the normal ovary. Int J Cancer 74:275-280
32. 32. Davies BR, Worsley SD, Ponder BA 1998 Expression of E-cadherin, α-catenin and β-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology 32:69-80
33. 33. Midgley CA, White S, Howitt R, Save V, Dunlop M, Hall PA, Lane DP, Wyllie AH, Bubb VJ 1997 APC expression in normal human tissues. J Pathol 181:426-433
34. 34. Peralta Soler A, Knudsen KA, Jaurand M-C, Johnson KR, Wheelock MJ, Klein-Szanto A, Salazar H 1995 The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Hum Pathol 26:1363-1369
35. 35. Gulatl R, Peluso JJ 1997 Opposing actions of hepatocyte growth factor and basic fibroblast growth factor on cell contact, intracellular free calcium levels, and rat ovarian surface epithelial cell viability. Endocrinology 138:1847-1856
36. 36. Wong AST, Maines-Bandiera SL, Rosen B, Wheelock MJ, Johnson KR, Leung PCK, Roskelley CD, Auersperg N 1999 Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: influence of family history of ovarian cancer. Int J Cancer 81:180-188
37. 37. van der Linden PJQ, Goeij de AFPM, Dunselman GAJ, Erkens HWH, Evers JLH 1995 Expression of cadherins and integrins in human endometrium throughout the menstrual cycle. Fertil Steril 63:1210-1216
38. 38. MacCalman CD, Farooki R, Blaschuk OW 1994 Estradiol regulates E-cadherin mRNA levels in the surface epithelium of the mouse ovary. Clin Exp Metastasis 12:276-282
39. 39. Ryan PL, Valentine AF, Bagnell CA 1996 Expression of epithelial cadherin in the developing and adult pig ovary. Biol Reprod 55: 1091-1097
40. 40. Maines-Bandiera SL, Auersperg N 1997 Increased E-cadherin expression in ovarian surface epithelium: an early step in metaplasia and dysplasia? Int J Gynecol Pathol 16:250-255
41. 41. MacCalman CD, Farooki R, Blaschuk OW 1994 Estradiol and progestrone regulate E-cadherin mRNA levels in the mouse uterus. Endocrine 2:485-490
42. 42. Marrs JA, Nelson WJ 1996 Cadherin cell adhesion molecules in differentiation and embryogenesis. Int Rev Cytol 165:159-175
43. 43. van der Linden PJQ, Goeij de AFPM, Dunselman GAJ, Arends JW, Evers JLH 1994 P-cadherin expression in human endometrium and endometriosis. Gynecol Obstet Invest 38:183-185
44. 44. Hoschnetzky H, Aberle H, Kelmes R 1994 β-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 127:1375-1380
45. 45. Brady-Kalnay SM, Rimm DL, Tonks NK 1995 Receptor protein tyrosine phosphatase PtPm associated with cadherins and catenins in vivo. J Cell Biol 130:977-986
46. 46. Gillett WR, Mitchell A, Hurst PR 1991 A scanning electron microscopic study of the human ovarian surface epithelium: characterization of two cell types. Hum Reprod 6:645-650
47. 47. Blaustein A, Kaganowicz A, Wells J 1982 Tumor markers in inclusion cysts of the ovary. Cancer 49:722-726
48. 48. Mittal KR, Goswami S, Demopoulos RI 1995 Immunohistochemical profile of ovarian inclusion cysts in patients with and without ovarian carcinoma. Histochem J 27:119-122
49. 49. van Niekerk CC, Boerman OC, Ramaekers FCS, Poels LG 1991 Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas. Am J Pathol 138: 455-463
50. 50. Deligdisch L, Einstein A, Guera D, Gil J 1995 Ovarian dysplasia in epithelial inclusion cysts. Cancer 76:1027-1034
51. 51. Scully RE 1995 Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Int J Gynecol Obstet 49[Suppl]:S9-S15
52. 52. Scully RE 1995 Pathology of ovarian cancer precursors. J Cell Biochem [Suppl] 23:208-218
53. 53. Radisavljevic S 1976 The pathogenesis of ovarian inclusion cysts and cystomas. Obstet Gynecol 49:424-429
54. 54. Murdoch WJ 1994 Ovarian surface epithelium during ovulatory and anovulatory ovine estrous cycles. Anat Rec 240:322-326
55. 55. Ziltener HJ, Maines-Bandiera S, Schrader JW, Auersperg N 1993 Secretion of bioactive interleukin-1, interleukin-6, and colony-stimulating factors by human ovarian surface epithelium. Biol Reprod 49:635-641
56. 56. Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS, Bast Jr RC 1993 Growth regulation and transformation of ovarian epithelium; Cancer 71:545-551
57. 57. Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast Jr RC 1992 Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-α. Am J Obstet Gynecol 166:997-1007
58. 58. Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg JB, Bast Jr RC 1993 Tumor necrosis factor α as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor a expression. Cancer Res 53:1939-1944
59. 59. Osterholzer H, Streibel EJ, Nicosia SV 1985 Growth effects of protein hormones on cultured rabbit ovarian surface epithelial cells. Biol Reprod 33:247-258
60. 60. Woodworth CD, Dipaolo JA 1994 Enhanced proliferation of human papilloma virus (HPV)-immortalized cervical and cervical carcinoma lines by rIL-1, IL-6 and TNF. Proc Am Assoc Cancer Res 35:569
61. 61. Bjersing L, Cajander S 1975 Ovulation and the role of the ovarian surface epithelium. Experientia 15:605-608
62. 62. Espey LL, Lipner H 1994 Ovulation. In: Knobil E, Neill JD (eds) The Physiology of Reproduction. Raven Press, Ltd, New York, pp 725-780
63. 63. Ackerman RC, Murdoch WJ 1993 Prostaglandin-induced apoptosis of ovarian surface epithelial cells. Prostaglandins 45:475-485
64. 64. Murdoch WJ 1995 Programmed cell death in preovulatory ovine follicles. Biol Reprod 53:8-12
65. 65. Quirk SM, Cowan RG, Huber SH 1997 Fas antigen-mediated apoptosis of ovarian surface epithelial cells. Endocrinology 138: 4558-4566
66. 66. Baldwin RL, Tran H, Karlan BY 1999 Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis. Gynecol Oncol 74:265-271
67. 67. Kruk PA, Auersperg N 1994 A line of rat ovarian surface epithelium provides a continuous source of complex extracellular matrix. In Vitro Cell Dev Biol 30:217-225
68. 68. Kruk PA, Auersperg N 1992 Human ovarian surface epithelial cells are capable of physically restructuring extracellular matrix. Am J Obstet Gynecol 167:1437-1443
69. 69. van Niekerk CC, Jap PHK, Thomas CMG, Smeets DFCM, Ramaekers FCS, Poels LG 1989 Marker profile of mesothelial cells vs. ovarian carcinoma cells. Int J Cancer 43:1065-1071
70. 70. Zeimet AG, Offner FA, Muller-Holzner E, Widschwendter M, Abendstein B, Fuith LC, Daxenbichler G, Marth C 1998 Peritoneum and tissues of the female reproductive tract as physiological sources of CA-125. Tumor Biol 19:275-282
71. 71. Czernobilsky B 1985 Co-expression of cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii cells of the human ovary. Eur J Cell Biol 37:175-190
72. 72. Hornby AE, Pan J, Auersperg N 1992 Intermediate filaments in rat ovarian surface epithelial cells: changes with neoplastic progression in culture. Biochem Cell Biol 70:16-25
73. 73. Gilles C, Polette M, Zahm J-M, Tournier J-M, Volders L, Foidart J-M, Birembaut P 1999 Vimentin contributes to human mammary epithelial cell migration. J Cell Sci 122:4615-4625
74. 74. Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, Arrick BA, Clarke-Pearson DL, Bast Jr RC 1992 Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-β. Am J Obstet Gynecol 166:676-684
75. 75. Toda S, Matsumura S, Fujitani N, Nishimura T, Yonemitsu N, Sugihara H 1997 Transforming growth factor-β1 induces a mesenchyme-like cell shape without epithelial polarization in thyrocytes and inhibits thyroid folliculogenesis in collagen gel culture. Endocrinology 138:5561-5575
76. 76. Davila RM, Crouch EC 1993 Role of mesothelial and submesothelial stromal cells in matrix remodeling following pleural injury. Am J Pathol 142:547-555
77. 77. Trelstad RL, Hayashi A, Hayashi K, Donahoe PK 1982 The epithelial-mesenchymal interface of the male rat mullerian duct: loss of basement membrane integrity and ductal regression. Dev Biol 92:27-40
78. 78. Dyck HG, Hamilton TC, Godwin AK, Lynch HT, Maines-Bandiera SL, Auersperg N 1996 Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neo-plastic progression and with a family history of ovarian cancer. Int J Cancer 69:429-436
79. 79. Kramer BS, Gohagan J, Prorok PC, Smart C 1993 A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 71:589-593
80. 80. Piver MS, Baker TR, Jishi MF, Sandecki AM, Tsukada Y, Natarajan N, Mettlin CJ, Blake CA 1993 Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 71:582-588
81. 81. Cramer DW, Welch WR 1983 Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717-721
82. 82. Fraumeni Jr JF, Grundy GW, Creagan ET, Everson RB 1975 Six families prone to ovarian cancer. Cancer 36:364-369
83. 83. Greene MH, Clark JW, Blayney DW 1984 The epidemiology of ovarian cancer. Semin Oncol 11:209-226
84. 84. Godwin AK, Testa J, Handel L, Liu Z, Vanderveer LA, Tracey PA, Hamilton TC 1992 Spontaneous transformation of rat ovarian surface epithelial cells implicates repeated ovulation in ovarian cancer etiology and is associated with clonal cytogenetic changes. J Natl Cancer Inst 84:592-601
85. 85. Testa J, Getts L, Salazar H, Liu Z, Handel LM, Godwin AK, Hamilton TC 1994 Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res 54: 2788-2784
86. 86. Ness RB, Cottreau C 1999 Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459-1467
87. 87. Auersperg N, Maines-Bandiera SL, Dyck HG 1997 Ovarian carcinogenesis and the biology of ovarian surface epithelium. J Cell Physiol 173:261-265
88. 88. Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD, Venter JC, Dunlop MG, Hamilton SR, Peterson GM, de la Chapelle A, Vogelstein B, Kinzler KW 1994 Mutations of two PMS homologues in herediatry nonpolyposis colon cancer. Nature 371:75-80
89. 89. Kote-Jaral Z, Eeles RA 1999 BRCA1, BRCA2 and their possible function in DNA damage response. Br J Cancer 81:1099-1102
90. 90. Xu CF, Solomon E 1996 Mutations of the BRCA1 gene in human cancer. Cancer Biol 7:33-40
91. 91. Gayther SA, Harrington P, Kharkevkh G, Garkavtseva RF, Ponder BA 1996 Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group. Am J Hum Genet 58: 451-456
92. 92. Romagnolo D, Annab LA, Thompson TE, Risinger JI, Terry LA, Barren JC, Afshari CA 1998 Estrogen upregulation of BRCA1 expression with no effect on localization. Mol Carcinog 22:102-109
93. 93. Fan S, Wang JA, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Fang Yuan Auborn KJ, Goldberg ID, Rosen EM 1999 BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284:1354-1356
94. 94. Favy DA, Maurizis J-C, Bignon Y-J, Bernard-Gallon DJ 1999 Prolactin-dependent up-regulation of BRCA1 expression in human breast cancer cell lines. Biochem Biophys Res Commun 158: 284-291
95. 95. Salazar H, Godwin AK, Daly MD, Laub PB, Hogan M, Rosenblum N, Boente MP, Lunch HT, Hamilton TC 1996 Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 88:1810-1820
96. 96. Werness BA, Afify AM, Bielat KL, Eltabbakh GH, Pver MS, Paterson JM 1999 Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum Pathol 30:151-157
97. 97. Sherman ME, Lee JS, Burks RT, Struewing JP, Durman RJ, Hartge P 1999 Histopathologic features of ovaries at increased risk for carcinoma. Int J Gynecol Pathol 18:151-157
98. 98. Stratton JF, Buckley CH, Lows D, Ponder BAJ and the United Kingdom Coordinating Committee of Cancer Research (UKC-CCR), Familial Ovarian Cancer Study Group 1999 Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. J Natl Cancer Inst 91:626-628
99. 99. Young RH, Clement PB, Scully RE 1989 The Ovarian. In: Sternberg SS (ed) Diagnostic Surgical Pathology. Raven Press, New York, pp 1655-1734
100. 100. Van Niekerk CC, Ramaekers FCS, Hanselaar AGJM, Aldeweireldt J, Poels LG 1993 Changes in expression of differentiation markers between normal ovarian cells and derived tumors. Am J Pathol 142:157-177
101. 101. Jiang X, Morland SJ, Hitchcock A, Thomas EJ, Campbell IG 1998 Allelotyping of endometriosis with adjacent ovarian carcinomas reveals evidence of a common lineage. Cancer Res 58:1707-1712
102. 102. Young RH, Gilks CB, Scully RE 1991 Mucinous tumors of the appendix associated with mucinous tumors of the ovary and Pseumyxoma peritonei. Am J Surg Pathol 15:415-429
103. 103. Kantak SS, Kramer RH 1998 E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J Biol Chem 273:16953-16961
104. 104. Karlan BY, Jones JL, Greenwald M, Lagasse LD 1995 Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. Am J Obstet Gynecol 173:97-104
105. 105. Mittal KR, Zeleniuch-Jacquotte A, Cooper JL, Demopoulos RI 1993 Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int J Gynecol Pathol 12:59-63
106. 106. Cordon-Cardo C, Mattes MJ, Melamed MR, Lewis JL, Old LJ, Lloyd KO 1985 Immunopathological analysis of a panel of mouse monoclonal antibodies reacting with human ovarian carcinomas and other human tumors. Int J Gynecol Pathol 4:121-30
107. 107. Nouwen EJ, Hendrix PG, Dauwe S, Eerdekens MW, De Broe ME 1987 Tumor markers in the human ovary and its neoplasms. A comparative immunohistochemical study. Am J Pathol 126: 230-242
108. 108. Tashiro H, Miyazaki K, Okamura H, Iwai A, Fukumoto M 1992 c-myc overexpression in human primary ovarian tumours: its relevance to tumour progression. Int J Cancer 50:828-833
109. 109. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM 1991 K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139:777-785
110. 110. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Bast Jr RC 1990 Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50:4087-4091
111. 111. Kohler M, Janz I, Wintzer HO, Wagner E, Bauknecht T 1989 The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res 9:1537-1547
112. 112. Kacinski BM, Carter D, Kohorn EI, Mittal K, Bloodgood RS, Donahue J, Kramer CA, Fischer D, Edwards R, Chambers SK, Chambers JT, Schwartz PE 1989 Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors. Yale J Biol Med 62:379-392
113. 113. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW 1999 PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99-102
114. 114. Bellacosa A de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Panici PB, Mancuso S, Neri G, Testa JR 1995 Molecular alterations of the AKT2 oncogens in ovarian and breast carcinomas. Int J Cancer 64:280-285
115. 115. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast Jr RC 1994 The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 170:246-252
116. 116. Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, Campbell IG 1998 Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58:2095-2097
117. 117. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast Jr RC 1999 NOEY2 (ARHI), an imprinted putative rumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 96:214-219
118. 118. Kruk PA, Maines-Bandiera SL, Auersperg N 1990 A simplified method to culture human ovarian surface epithelium. Lab Invest 63:132-136
119. 119. Auersperg N, Maines-Bandiera SL 2000 Culture and characterization of human ovarian surface epithelium. In: Bartlett JMS (ed) Ovarian Cancer Methods Protocols. Humana Press, Totowa, NJ, pp 169-173
120. 120. Elliott WM, Auersperg N 1990 Growth of normal ovarian surface epithelial cells (HOSE) in reduced serum and defined media. J Cell Biol 111:58 (Abstract)
121. 121. Elliott WM, Auersperg N 1993 Growth of normal human ovarian surface epithelial cells in reduced-serum and serum-free media. In Vitro Cell Dev Biol 29:9-18
122. 122. McNeil L, Hobson S, Nipper V, Rodland KD 1998 Functional calcium-sensing receptor expression in ovarian surface epithelial cells. Am J Obstet Gynecol 178:305-313
123. 123. Nakamura M, Katabuchi H, Ohba T, Fukumatsu Y, Okamura H 1994 Isolation, growth and characteristics of human ovarian surface epithelium. Virchows Arch 424:59-67
124. 124. Auersperg N, Maines-Bandiera SL, Dyck HG 1996 Phenotypic plasticity of ovarian surface epithelium: possible implications for ovarian carcinogenesis. In: Sharp T, Blackett R, Leake J, Berek F (eds) Ovarian Cancer 4. Chapman & Hall, London, pp 3-17
125. 125. Adams AT, Auersperg N 1985 A cell line, ROSE 199, derived from normal rat ovarian surface epithelium. Exp Cell Biol 53:181-188
126. 126. Auersperg N, Maclaren IA, Kruk PA 1991 Ovarian surface epithelium; autonomous production of connective tissue-type extra-cellular matrix. Biol Reprod 44:717-724
127. 127. Ohtake H, Katabuchi H, Tanaka N, Fukumatsu Y, Matsuura K, Okamura H 1999 Human ovarian surface epithelial cells can produce tissue-type plasminogen activator and plasminogen activator inhibitor-1. Jpn J Fertil Steril 44:51-56
128. 128. Hoffman AG, Burghardt RC, Tilley R, Auersperg N 1993 An in vitro model of ovarian epithelial carcinogenesis: changes in cell-cell communication and adhesion occurring during neoplastic progression. Int J Cancer 54:828-838
129. 129. Gulati R, Peluso JJ 1997 Opposing actions of hepatocyte growth factor and basic fibroblast growth factor on cell contact, intracellular free calcium levels, and rat ovarian surface epithelial cell viability. Endocrinology 138:1847-1856
130. 130. Matsuura K, Ohtake H, Katabuchi H, Okamura H 1999 Coelomic metaplasia theory of endometriosis: evidence from in vivo studies and an in vitro experimental model. Gynecol Obstet Invest 47[Suppl 1]:18-22
131. 131. Ohtake H, Katabuchi H, Matsuura K, Okamura H 1999 A novel in vitro experimental model for ovarian endometriosis: the three-dimenstional culture of human ovarian surface epithelial cells in collagen gels, Fertil Steril 71:50-55
132. 132. Maines-Bandiera SL, Kruk PA, Auersperg N 1992 Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extra-cellular matrix. Am J Obstet Gynecol 167:729-735
133. 133. Tsao S-W, Mok SC, Fey EG, Fletcher JA, Wan TSK, Chew E-C, Muto MG, Knapp RC, Berkowitz RS 1995 Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs), Exp Cell Res 218: 499-507
134. 134. Wan TSK, Chan LC, Ngan HYS, Tsao S-W 1997 High frequency of telomeric associations in human ovarian surface epithelial cells transformed by human papilloma viral oncogenes. Cancer Genet Cytogenet 95:166-172
135. 135. May P, May E 1999 Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18:7621-7636
136. 136. Stiegler P, Kasten M, Giordano A 1998 The RB family of cell cycle regulatory factors. J Cell Biochem 31:30-36
137. 137. Wen W-H, Reles A, Runnebaum IB, Sullivan-Halley J, Bernstein L, Jones LA, Felix JC, Kreienberg R, El-Naggar A, Press MF 1999 p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol 18:29-41
138. 138. Parrott JA, Mosher R, Kim G, Skinner MK 2000 Autocrine interactions of keratinocyte growth factor hepatocyte growth factor and kit-ligand in the regulation of normal ovarian surface epithelial cells. Endocrinology 141:2532-2539
139. 139. Wong AST, Leung PCK, Auersperg N 1999 Hepatocyte growth factor/scatter factor and its receptor c-MET in cultured human ovarian surface epithelium: influence of family history of ovarian cancer. Proc Soc Study Reprod 32:95-96 (Abstract)
140. 140. Kruk PA, Godwin AK, Hamilton TC, Auersperg N 1999 Telomeric instability and reduced proliferative potential in ovarian surface epithelial cells from women with a family history of ovarian cancer. Gynecol Oncol 73:229-236
141. 141. Auersperg N, Maines-Bandiera S, Booth JH, Lynch HT, Godwin AK, Hamilton TC 1995 Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer. Am J Obstet Gynecol 173:558-565
142. 142. Brinkmann V, Foroutan H, Sachs M, Weidner KM, Birchmeier W 1995 Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells. J Cell Biol 131:1573-1586
143. 143. Auersperg N, Maines-Bandiera S, Kruk PA 1995 Human ovarian surface epithelium: growth patterns and differentiation. In: Sharp F, Mason WP (eds) Ovarian Cancer. Biology, Diagnosis and Management. Chapman & Hall, London, vol 3:157-169
144. 144. Jeffers M, Rong S, Woude GF 1996 Hepatocyte growth factor/scatter factor-met signaling in tumorigenicity and invasion/metastasis. J Mol Med 74:505-513
145. 145. Moghul A, Lin L, Beedle A, Kanbour-Shakir A, DeFrances MC, Liu Y, Zarnegar R 1994 Modulation of c-met proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8-kb c-met transcript. Oncogene 9:2045-2052
146. 146. Di Renzo MF, Olivero M, Katsaros D, Crepald T, Gaglia P, Zola P, Sismondi P, Comoglio PM 1994 Overexpression of the Met/ HGF receptor in ovarian cancer. Int J Cancer 58:658-662
147. 147. Huntsman D, Resau JH, Klineberg E, Auersperg N 1999 Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. Am J Pathol 155:343-348
148. 148. Goldberg JM, Piver SM, Jishi MF, Blumenson L 1997 Age at onset of ovarian cancer in women with a strong family history of ovarian cancer. Gynecol Oncol 66:3-9
149. 149. Fathalla MF 1971 Incessant ovulation-a factor in ovarian neoplasia? Lancet 2:163
150. 150. Kang SK, Choi K-C, Cheng KW, Nathwani PS, Auersperg N, Leung PCK 2000 Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. Endocrinology 141:72-80
151. 151. Davies BR, Finnigan DS, Smith SK, Ponder BA 1999 Administration of gonadotropins stimulates proliferation of normal mouse ovarian surface epithelium. Gynecol Endocrinol 13:75-81
152. 152. Zheng W, Magid MS, Kramer EE, Chen YT 1996 Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and Fallopian tube. Am J Pathol 148:47-53
153. 153. te Velde ER, Scheffer GJ, Dorland M, Broekmans FJ, Fauser BCJM 1998 Developmental and endocrine aspects of normal ovarian aging. Mol Cell Endocrinol 145:67-73
154. 154. Hess S, Gulati R, Peluso JJ 1999 Hepatocyte growth factor induces rat ovarian surface epithelial cell mitosis or apoptosis depending on the presence or absence of an extracellular matrix. Endocrinology 140:2908-2916
155. 155. Lau K-M, Mok SC, Ho S-M 1999 Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 96:5722-5727
156. 156. Brandenberger AN, Tee MK, Jaffe RB 1998 Estrogen receptor α (ER-α) and β (ER-β) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-depletion of ER-β in neoplastic tissues. J Clin Endocrinol Metab 83:1025-1028
157. 156a. Kang SK, Choi K-C, Tai CJ, Auersperg N, Leung PC 2001 Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and modulates the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells. Endocrinology 142:580-588
158. 157. Liu Y, Lin L, Zarnegar R 1994 Modulation of hepatocyte growth factor gene expression by estrogen in mouse ovary. Mol Cell Endocrinol 104:173-181
159. 158. Evangelou A, Jindal SK, Brown TJ, Letarte M 2000 Down-regulation of transforming growth factor β receptors by androgen in ovarian cancer cells. Cancer Res 60:929-935
160. 159. Nash DM, Hess SA, White BA, Peluso JJ 1998 Steroidogenic factor-1 regulates the rate of proliferation of normal and neoplastic rat ovarian surface epithelial cells in vitro. Endocrinology 139:4663-4671
161. 160. Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast Jr RC 1991 Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol 164:745-750
162. 161. Pierro E, Nicosia SV, Saunders B, Fultz CB, Nicosia RF, Mancuso S 1996 Influence of growth factors on proliferation and morphogenesis of rabbit ovarian mesothelial cells in vitro. Biol Reprod 54:660-669
163. 162. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, Bast Jr RC 1991 Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 164:669-674
164. 163. Oka Y, Orth DN 1983 Human plasma epidermal growth factor/B-urogastrone is associated with blood platelets. J Clin Invest 72: 249-259
165. 164. Gillet JY, Maillet R, Gautier C 1980 Blood supply and lymph supply of the ovary. In: Motta PM, Makabe ESE (eds) Biology of the Ovary, Martinus Nijhoff Publishers, Boston, pp 86-98
166. 165. Mondshein JS, Schomberg DW 1981 Growth factors modulate gonadotropin receptor induction in granulosa cell cultures. Science 211:1179-1180
167. 166. Hsueh AJW, Welsh TH, Jones PBC 1981 Inhibition of ovarian and testicular steroidogensis by epidermal growth factor. Endocrinology 108:2002-2004
168. 167. Erickson GF, Case E 1983 Epidermal growth factor antagonizes ovarian theca-interstitial cytodifferentiation. Mol Cell Endocrinol 31:71-76
169. 168. Knecht M, Catt KJ 1983 Modulation of cAMP-mediated differentiation in ovarian granulosa cell by epidermal growth factor and platelet-derived growth factor. J Biol Chem 258:2789-2794
170. 169. Jindal SK, Snoey DM, Lobb DK, Dorrington JH 1994 Transforming growth factor α localization and role in surface epithelium of normal human ovaries and in ovarian carcinoma cells. Gynecol Oncol 53:17-23
171. 170. McLellan M, Kievit P, Auersperg N, Rodland K 1999 Regulation of proliferation and apoptosis by epidermal growth factor and protein kinase C in human ovarian surface epithelial cells. Exp Cell Res 246:471-479
172. 171. Johnson GR, Saeki T, Auersperg N, Gordon AW, Shoyab M, Salomon DS, Stromberg K 1991 Response to and expression of amphiregulin by ovarian carcinoma and normal ovarian surface epithelial cells: nuclear localization of endogenous amphiregulin. Biochem Biophys Res Commun 80:481-488
173. 172. Gordon AW, Pegues JC, Johnson GR, Kannan B, Auersperg N, Stromberg K 1994 mRNA phenotyping of the major ligands and receptors of the EGF supergene family in human epithelial cells. Cancer Lett 89:63-71
174. 173. Aguilar Z, Akita RW, Finn RS, Ramos BL, Pegram MD, Kabbinavar FF, Pietras RJ, Pisacane P, Sliwkowski MX, Slamon DJ 1999 Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene 18:6050-6062
175. 174. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Watetfield MD 1984 Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307:521-527
176. 175. Klapper LN, Kirschbaum MH, Sela M, Yarden Y 2000 Biochemical and clinical implications of the erbB/HER signaling network of growth factor receptors. In: Advances in Cancer Research, Academic Press, New York, pp 25-79
177. 176. Kohler M, Bauknecht T, Grimm M, Birmelin G, Kommoss F, Wagner E 1992 Epidermal growth factor receptor and transforming growth factor α expression in human ovarian carcinomas. Eur J Cancer 28:1432-1437
178. 177. Owens OJ, Stewart C, Brown I, Leake RE 1991 Epidermal growth factor receptors (EGFR) in human ovarian cancer. Br J Cancer 64:907-910
179. 178. Basilico C, Moscatelli D 1992 FGF family of growth factors and oncogenes. Adv Cancer Res 59:115-165
180. 179. Trolice MP, Pappalardo A, Peluso JJ 1997 Basic fibroblast growth factor and N-cadherin maintain rat granulosa cell and ovarian surface epithelial cell viability by stimulating the tyrosine phosphorylation of the fibroblast growth factor receptors. Endocrinology 138:107-113
181. 180. Dabrow MB, Francesco MR, McBrearty FX, Caradonna S 1998 The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol 71:29-37
182. 181. Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Muller-Holzner E, Offner F, Feichtinger H, Zwierzina H, Daxenbichler G 1996 Different effects of interferons, interleukin-1β and tumor necrosis factor-α in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer 67:826-830
183. 182. Taipale J, Saharinen J, Keski-Oja J 1998 Extracellular matrix-associated transforming growth factor-β: role in cancer cell growth and invasion. In: Advances in Cancer Research, Academic Press, New York, pp 87-134
184. 183. Vigne J-L, Halburnt LL, Skinner MK 1994 Characterization of bovine ovarian surface epithelium and stromal cells: identification of secreted proteins. Biol Reprod 51:1213-1221
185. 184. Havrilesky LJ, Hurteau JA, Whitaker RS, Elbendary A, Wu S, Rodriguez GC, Bast Jr RC, Berchuck A 1995 Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor β1. Cancer Res 55:944-948
186. 185. Ismail RS, Cada M, Vanderhyden BC 1999 Transforming growth factor-β regulates Kit ligand expression in rat ovarian surface epithelial cells. Oncogene 18:4734-4741
187. 186. Henriksen R, Gobl A, Wilander E, Oberg K, Miyazone K, Funa K 1995 Expression and prognostic significance of TGF-β isotypes, latent TGF-β1 binding protein, TGF-β type 1 and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest 73:213-220
188. 187. Welt CK, Lambert-Messerlian G, Zheng W, Crowley Jr WF, Schneyer AL 1997 Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab 82:3720-3727
189. 188. Josso N, Racine C, di Clemente N, Rey R, Xavier F 1998 The role of anti-Mullerian hormone in gonadal develoment. Mol Cell Endocrinol 145:3-7
190. 189. Bottaro DP, Robins JS, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA 1991 Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:801-804
191. 190. Di Renzo MF, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, Gaglia P, Zara F, Comoglio PM 1991 Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 6:1997-2003
192. 191. Sonnenberg E, Meyer D, Weidner M, Birchmeier C 1993 Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 123:223-235
193. 192. Parrott JA, Vigne J-L, Chu BZ, Skinner MK 1994 Mesenchymal-epithelial interactions in the ovarian follicle involve keratinocyte and hepatocyte growth factor production by thecal cells and their action on granulosa cells. Endocrinology 135:569-575
194. 193. Negami AI, Sasaki H, Kawakami Y, Kamitani N, Kotsuji F, Tominaga T, Nakamura T 1995 Serum human hepatocyte growth factor in human menstrual cycle and pregnancy: a novel serum marker of regeneration and reconstruction of human endometrium, Horm Res 44[Suppl 2]:42-46
195. 194. Klominek J, Baskin B, Liu Z, Hauzenberger D 1998 Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor. Int J Cancer 76:240-249
196. 195. Wolf HK, Zarnegar R, Michalopolous GK 1991 Localization of hepatocyte growth factor in human and rat tissues: an immunohistochemical study. Hepatology 14:488-494
197. 196. Parrott JA, Skinner MK 2000 Expression and action of hepatocyte growth factor in human and bovine normal ovarian surface epithelium and ovarian cancer. Biol Reprod 62:491-500
198. 197. Yang X-M, Park M 1995 Expression of the hepatocyte growth factor/scatter factor tyrosine kinase is localized to epithelia in the adult mouse. Lab Invest 73:483-491
199. 198. Robertson SA, Mayrhofer G, Seamark RF 1996 Ovarian steroid hormones regulate granulocyte-macrophage colony-stimulating factor synthesis by uterine epithelial cells in the mouse. Biol Reprod 54:183-196
200. 199. Braden TD, Conn PM 1993 GnRH and its mechanism of action. In: Leung PCK, Hsueh AJW, Friesen HG (eds) Molecular Basis of Reproductive Endocrinology. Springer-Verlag, New York, pp 12-38
201. 200. Conn PM 1994 The molecular mechanism of gonadotropin-releasing hormone action in the pituitary. In: Knobil E, Neill JD (eds) The Physiology of Reproduction. Raven Press Ltd., New York, pp 1815-1826
202. 201. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Holzel F, Schultz KD, Schally AV 1993 High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53:5439-5446
203. 202. Emons G, Ortmann O, Pahwa GS, Oberheuser F, Schulz KD 1992 LH-RH agonists in the treatment of ovarian cancer. Recent Results Cancer Res 124:55-68
204. 203. Emons G, Schroder B, Ortmann O, Westphalen W, Schulz KD, Schally AV 1993 High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 77: 1458-1464
205. 204. Gallagner CJ, Oliver RTD, Orar DH, Fouler CG, Blake PR, Hantell BS, Slevin ML, Hopestone HF 1991 A new treatment for endometrial cancer with gonadotropin-releasing hormone analogues. Br J Obstet Gynecol 98:1037-1041
206. 205. Harris AL, Carmichael J, Cantwell BMJ, Dowsett MZ 1989 Endocrine and therapeutic effects in postmenopausal breast cancer. Br J Cancer 59:97-99
207. 206. Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J 1990 The effects of gonadotropin-releasing hormone receptor analogues in prostate cancer cell are mediated through specific tumor receptor. Br J Cancer 62:96-99
208. 207. Emons G, Ortmann O, Schulz KD, Schally AV 1997 Growth inhibitory actions of analogues of luteunizing hormone-releasigh hormone on tumor cells. Trends Endocrinol Metab 8:355-362
209. 208. Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, Groot K, Armatis P 1997 Growth inhibition of human ovarian cancers by cytoxic analogues of luteinizing hormone-releasing hormone. J Natl Cancer Inst 89:1803-1809
210. 209. Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas ATA, Comaru-Schally AM, Schally AV 1982 Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists, Proc Natl Acad Sci USA 79: 1658-1662
211. 210. Klijn JGM 1984 Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatment. Med Oncol Tumor Pharmacother 1:123-128
212. 211. Peterson CM, Jolles CJ, Carrell DT, Straight RC, Jones KP, Poulson AM, Hatasaka HH 1994 GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience. Gynecol Oncol 52:26-30
213. 212. Mortel R, Stayaaswaroop PG, Schally AV, Hamilton TC, Ozols R 1986 Inhibitory effect of GnRH superagonist on the growth of human ovarian carcinoma NIH: OVCAR3 in the nude mouse. Gynecol Oncol 23:254-255
214. 213. Maruuchi T, Sugiyama T, Kataoka A, Nishida T, Yakushiji M 1998 Effects of a gonadotropin-releasing hormone agonist on rat ovarian adenocarcinoma cell lines in vitro and in vivo. Jpn J Cancer Res 89:977-983
215. 214. Yano T, Pinski J, Radulovic S, Schally AV 1994 Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 91:1701-1705
216. 215. Medl M, Peters-Engel C, Fuchs G, Leodolter S 1993 Triptorelin (D-Trp-6-LHRH) in combination with carboplatin-containing polychemotherapy for advanced ovarian cancer: a pilot study. Anti-cancer Res 13:2373-2376
217. 216. Schally AV, Nagy A 1999 Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors to tumors. Eur J Endocrinol 141:1-14
218. 217. Szepeshazi K, Schally AV, Juhasz A, Nagy A, Janaky T 1992 Effects of luteinizing hormone-releasing hormones analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo. Anticancer Drugs 3:109-116
219. 218. Kahan Z, Nagy A, Schally AV, Halmos G, Arecibia JM, Groot K 1999 Complete regression of MX-1 human breast cancer xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. Cancer 85:2608-2615
220. 219. Miyazaki M, Schally AV, Nagy A, Lamharzi N, Halmos G, Szepeshazi K, Armatis P 1999 Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. Am J Obstet Gynecol 180:1095-1103
221. 220. Szepeshazi K, Schally AV, Nagy A, Halmos G, Groot K 1997 Targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analogs inhibit growth of estrogen-independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis. Anti-Cancer Drugs 8:974-984
222. 221. Koppan M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM, Groot K 1999 Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate 38:151-158
223. 222. Thomson MA, Adelson MP, Kaufman LM 1991 Lupron retards proliferation of ovarian epithelial tumor ells cultured in serum free medium. J Clin Endocrinol Metab 72:1036-1041
224. 223. Emons G, Müllet V, Ortmann O, Schulz KD 1998 Effects of LHRH-analogues on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol 65:199-206
225. 224. Lee MT, Liebow C, Kramer AR, Schally AV 1991 Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various rumors. Proc Natl Acad Sci USA 88:1656-1660
226. 225. Imai A, Takagi H, Furui T, Horibe S, Fuseya T, Tamaya T 1996 Evidence for coupling for phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane. Cancer 77:132-137
227. 226. Emons G, Müller V, Ortmann O, Grossmann G, Trautner U, Stuckrad B, Schulz KD, Schally AV 1996 Luteinizing hormone-releasing hormone agonist triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines. Int J Oncol 9:1129-1137
228. 227. Hershkovitz E, Marbach M, Bosin E, Joseph L, Roberts CT, Leroith D, Schally AV, Sharoni Y 1993 Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. J Clin Endocrinol Metab 77:963-968
229. 228. Marelli MM, Moretti RM, Dondi D, Motta M, Limonta P 1999 Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology 140: 329-334
230. 1 protein in human reproductive tract tumors. J Clin Endocrinol Metab 81:3249-3253
231. 230. Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M, Motta M 1999 The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 140:5250-5256
232. 231. Sridaran R, Hisheh S, Dharmarajan AM 1998 Induction of apoptosis by a gonadotropin-releasing hormone agonist during early pregnancy in the rat. Apoptosis 3:51-57
233. 232. Motomura S 1998 Induction of apoptosis in ovarian carcinoma cell line by gonadotropin-releasing hormone agonist. Kurume Med J 45:27-32
234. 233. Nagata S, Golstein P 1995 The Fas death factor. Science 267:1449-1456
235. 234. Ohta H, Sakamoto H, Satoh K 1998 In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on cancer cell sensitivity to cis-platinum. Cancer Lett 134:111-118
236. 235. Risch HA 1998 Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90:1774-1786
237. 236. Whittemore AS, Harris R, Itnyre J 1992 Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 136:1175-1220
238. 237. Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG 1996 Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 65:13-18
239. 238. Shoham Z 1994 Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: where are we today? Fertil Steril 62:433-448
240. 239. Rao BR, Slotman BJ 1991 Endocrine factors in common epithelial ovarian cancer. Endocr Rev 12:14-26
241. 240. Mandai M, Konishi I, Kuroda H, Fukumoto M, Komatsu T, Yamamoto S, Nanbu K, Rao CV, Mori T 1997 Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas. Eur J Cancer 33:1501-1507
242. 241. Konishi I, Kuroda H, Mandai M 1999 Review: gonadotropins and development of ovarian cancer. Oncology 57:45-48
243. 242. Zheng W, Lu JJ, Luo F, Zheng Y, Feng Yj, Felix JC, Lauchlan SC, Pike MC 2000 Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 76:80-88
244. 243. Wimalasena J, Dostal R, Meehan D 1992 Gonadotropins, estradiol, and growth factors regulate epithelial ovarian cancer cell growth. Gynecol Oncol 46:345-350
245. 244. Kurbacher CM, Jager W, Kurbacher JA, Bittl A, Wildt L, Lang N 1995 Influence of human luteinizing hormone on cell growth and CA 125 secretion of primary epithelial ovarian carcinomas in vitro. Tumour Biol 16:374-384
246. 245. Schiffenbauer YS, Abramovitch R, Meir G, Nevo N, Holzinger M, Itin A, Keshet E, Neeman M 1997 Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci USA 94:13203-13208
247. 246. Franceschi S, La Vecchia C, Negri E, Guameri S, Montella M, Conti E, Parazzini F 1994 Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum Reprod 9:1673-1675
248. 247. Venn A, Watson L, Lumley J, Giles G, King C, Healy D 1995 Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 346:995-1000
249. 248. Wimalasena J, Meehan D, Cavallo C 1991 Human epithelial ovarian cancer cell steroid secretion and its control by gonadotropins. Gynecol Oncol 41:56-63
250. 249. Wimalasena J, Meehan D, Dostal R, Foster JS, Cameron M, Smith M 1993 Growth factors interact with estradiol and gonadotropins in the regulation of ovarian cancer cell growth and growth factor receptors. Oncol Res 5:325-337
251. 250. Kuroda H, Mandai M, Konishi I, Yura Y, Tsuruta Y, Hamid AA, Nanbu K, Matsushita K, Mori T 1998 Human chorionic gonadotropin. (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of insulin-like growth factor-1 by hCG. Int J Cancer 76:571-578
252. 251. Mathews LS 1994 Activin receptors and cellular signaling by the receptor serine kinase family. Endocr Rev 15:310-325
253. 252. Vale W, Rivier C, Hsueh A, Campen C, Meunier H, Bicsak T, Vaughan J, Corrigan A, Bardin W, Sawchenko P 1988 Chemical and biological characterization of the inhibin family of protein hormones. Prog Horm Res 44:1-34
254. 253. Woodruff TK 1998 Regulation of cellular and system function by activin. Biochem Pharmacol 55:953-963
255. 254. Ling N, Ying SY, Ueno N, Shimasaki S, Esch F, Hotta M, Guillemin R 1986 Pituitary FSH is released by a heterodimer of the β-subunits from the two forms of inhibin. Nature 321:779-782
256. 255. Vale W, Rivier J, Vaughan J, McClintock R, Corrigan A, Woo W, Karr D, Spiess J 1986 Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 321: 776-778
257. 256. Eramaa M, Heikinheimo K, Tuuri T, Hilden K, Ritvos O 1993 Inhibin/activin subunit mRNA expression in human granulosaluteal cells. Mol Cell Endocrinol 92:R15-R20
258. 257. Tuuti T, Eramaa M, Van Schaik RHN, Ritvos O 1996 Differential regulation of inhibin/activin α- and βA-subunit and follistatin mRNAs by cyclic AMP and phorbol ester in cultured human granulosa-luteal cells. Mol Cell Endocrinol 121:1-10
259. 258. Eramaa M, Hilden K, Tuuri T, Ritvos O 1995 Regulation of inhibin/activin subunit messenger ribonucleic acids (mRNAs) by activin A and expression of activin receptor mRNAs in cultured human granulosa-luteal cells. Endocrinology 136:4382-4389
260. 258a. Choi K-C, Kang SK, Nathwani PS, Cheng PW, Auersperg N, Leung PC, Differential expression of activin/inhibin subunit and activin receptor mRNAs in normal and neoplastic ovarian surface epithelium (OSE). Mol Cell Endocrinol, in press
261. 259. Di Simone N, Crowley Jr WF, Wang QF, Sluss PM, Schneyer AL 1996 Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 137: 486-494
262. 260. Fukuda J, Ito I, Tanaka T, Leung PCK 1998 Cell survival effect of activin against heat shock stress on OVCAR-3. Life Sci 63:2209-2220
263. 261. Zheng W, Luo MP, Welt C, Lambert-Messerlian G, Sung CJ, Zhang Z, Ying SY, Schneyer AL, Lauchlan SC, Felix JC 1998 Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol 69:23-31
264. 262. Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M, Grant P, Day AJ, Rome R, Campbell JJ 1993 Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 329:1539-1542
265. 263. Healy DL, Mamers P, Bangah M, Burger HG 1993 Clinical and pathophysiological aspects of inhibin. Hum Reprod 8[Suppl 2]:138-140
266. 264. Lambert-Messerlian GM, Steinhoff M, Zheng W, Cankk JA, Gajewski WH, Seifer DB, Schneyer AL 1997 Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer. Gynecol Oncol 65:512-516
267. 265. Robertson DM, Cahir N, Burger HG, Mamers P, Groome N 1999 Inhibin forms in serum from postmenopausal women with ovarian cancers. Clin Endocrinol (Oxf) 50:381-386
268. 266. Burger HG, Robertson DM, Cahir N, Mamers P, Healy DL, Jobling T, Groome N 1996 Characterization of inhibin immuno-reactivity in post-menopausal women with ovarian tumours. Clin Endocrinol (Oxf) 44:413-418
269. 267. Burger HG, Baillie A, Drummond AE, Healy DL, Jobling T, Mamers P, Robertson DM, Susil B, Cahir N, Shen Y, Verity K, Fuller PJ, Groome NP, Findlay JK 1998 Inhibin and ovarian cancer. J Reprod Immunol 39:77-87
270. 268. Fuller PJ, Chu S, Jobling T, Mamers P, Healy DL, Burger HG 1999 Inhibin subunit gene expression in ovarian cancer. Gynecol Oncol 73:273-279
271. 269. Ala-Fossi SL, Grenman S, Zhang FP, Blauer M, Punnonen R, Maenpaa J 1999 Ovarian cancer and gonadotropins in vitro: new evidence in favor of independence. Anticancer Res 19:4289-4295
272. 270. Young RC, Knapp RC, Fuks Z, DiSaia PJ 1985 Principles and practice of oncology. In: Devita jr VT, Hellman S, Rosenberg SA (eds) Cancer. Lippincott, Philadelphia, pp 1083-1076
273. 271. Hoover R, Gray LA, Fraumeni JF 1977 Stilboestrol (diethylstilbestrol) and the risk of ovarian cancer. Lancet 2:533-534
274. 272. Chien C, Wang F, Hamilton TC 1994 Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells. Mol Cell Endocrinol 99:11-19
275. 273. Galtier-Dercure F, Capony F, Maudelonde T 1992 Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kiloDalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 75:1497-1502
276. 274. Langon SP, Hirst GI, Miller EP, Hawkins RA, Tesdale AI, Smyth JF, Miller WR 1994 The regulation of growth and protein expression by estrogen in vitro: a study of eight human ovarian carcinoma cell lines. J Steroid Biochem Mol Biol 50:131-135
277. 275. Rodriguez C, Calle EE, Coates RJ, Miracle-McMahill HL, Thun MJ, Heath Jr CW 1995 Estrogen replacement therapy and fetal ovarian cancer. Am J Epidemiol 141:828-835
278. 276. Garg PP, Kerlikowske K, Subak L, Grady D 1998 Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92:472-479
279. 277. Clinton GM, Hua W 1997 Estrogen action in human ovarian cancer. Crit Rev Oncol Hematol 25:1-9
280. 278. Liu J, Rebar RW, Yen SS 1983 Neuroendocrine control of the postpartum period. Clin Perinatol 10:723-736
281. 279. Backstrom T, Mahlck C-G, Kjellgren O 1983 Progesterone as a possible tumor marker for "nonendocrine" ovarian malignant tumors. Gynecol Oncol 16:129-138
282. 280. Mahlck C-G, Backstrom T, Kjellgren O, Selstam G 1985 Plasma 20α-OH-progesterone in women with malignant epithelial "non-endocrine" ovarian tumors. Acta Obstet Gynecol Scand 64:515-518
283. 281. Mahlck C-G, Backstrom T, Kjellgren O 1986 Androstenedione production by malignant epithelial ovarian tumors. Gynecol Oncol 25:217-222
284. 282. Mahlck C-G, Grankvist K, Backstrom T, Kjellgren O 1986 Testosterone, SHBG and albumin in patients with ovarian carcinoma. Acta Obstet Gynecol Scand 65:533-538
285. 283. Mahlck C-G, Backstrom T, Kjellgren O 1988 Plasma levels of estradiol in patients with ovarian malignant tumors. Gynecol Oncol 30:313-320
286. 284. Heinonen PK, Koivula T, Rajaniemi H, Pystynen P 1986 Peripheral and ovarian venous concentrations of steroid and gonadotropin hormones in postmenopausal women with epithelial ovarian tumors. Gynecol Oncol 25:1-10
287. 285. Aiman J, Forney JP, Parker Jr CR 1986 Secretion of androgens and estrogens by normal and neoplastic ovaries in postmenopausal women. Obstet Gynecol 68:1-5
288. 286. Kitayama S, Nakano R 1990 Peripheral and ovarian venous concentrations of estradiol and progesterone in postmenopausal women with "non-endocrine" ovarian tumors. Acta Obstet Gynecol Scand 63:245-248
289. 287. Vihko R, Isotalo H, Kauppila A, Vierikko P 1983 Female sex steroid receptors in gynecological malignancies: clinical correlates. J Steroid Biochem 19:827-832
290. 288. Vierikko P, Kauppila A, Vihko R 1983 Cytosol and nuclear estrogen and progestin receptors and 17 β-hydroxysteroid dehydrogenase activity in non-diseased tissue and in benign and malignant tumors of the human ovary. Int J Cancer 31:413-422
291. 289. Willcocks D, Toppila M, Hudson CN, Tyler JP, Baird PJ, Eastman CJ 1983 Estrogen and progesterone receptors in human ovarian tumors, Gynecol Oncol 16:246-253
292. 290. Wurz H, Wassner E, Citoler P, Schulz K-D, Kaiser R 1983 Multiple cytoplasmic steroid hormone receptors in benign and malignant ovarian tumors and in disease-free ovaries. Tumor Diagn Ther 4:15-20
293. 291. Lantta M 1984 Estradiol and progesterone receptors in normal ovary and ovarian tumors, Acta Obstet Gynecol Scand 63:497-503
294. 292. Toppila M, Tyler JPP, Fay R, Baird PJ, Craindon AJ, Eastman CJ, Hudson CN 1986 Steroid receptors in human ovarian malignancy. A review of four years tissue collection. Br J Obstet Gynaecol 93:986-992
295. 293. Bibro MC, Schwartz PE, LiVolsi VA, Eisenfeld AJ 1979 Estrogen binding marcomolecules in human ovarian carcinoma. Lab Invest 40:241-242
296. 294. Schwartz PE, LiVolsi VA, Hildreth N, MacLusky NJ, Naftolin FN, Eisenfeld AJ 1982 Estrogen receptors in ovarian epithelial carcinoma. Obstet Gynecol 59:229-238
297. 295. Anderl P, Fuith LC, Daxenbichler G, Marth C, Dapunt O 1988 Correlation between steroid hormone receptors, histological and clinical parameters in ovarian carcinoma. Gynecol Obstet Invest 25:135-140
298. 296. Nestok BR, Masood S, Lammert N 1988 Correlation of hormone receptors with histologie differentiation in ovarian carcinoma. J Fla Med Assoc 75:731-733
299. 297. Harding M, Cowan S, Hole D, Cassidy L, Kitchener H, Davis J, Leake R 1990 Estrogen and progesterone receptors in ovarian cancer. Cancer 65:486-491
300. 298. Friedman M, Lagios M, Markowitz A, Jones H, Resser K, Hoffman P 1979 Estradiol (ER) and progesterone receptors (PR) in ovarian cancer: clinical and pathological correlation. Clin Res 27: 358A (Abstract)
301. 299. Teufel G, Geyer H, De Gregorio G, Fuchs A, Kleine W, Pfleiderer A 1983 Oestrogen- und progesteronerezeptoren in malignen ovarialtumoren. Geburtshilfe Frauenheilkd 43:732-740
302. 300. Ford LC, Berek JS, Lagasse LD, Hacker NF, Heins Y, Esmailian F, Leuchter RS, DeLange RJ 1983 Estrogen and progesterone receptors in ovarian neoplasms. Gynecol Oncol 15:299-304
303. 301. Iversen O-E, Skaarland E, Utaaker E 1986 Steroid receptor content in human ovarian tumors: survival of patients with ovarian carcinoma related to steroid receptor content. Gynecol Oncol 23:65-76
304. 302. Quinn MA, Pearce P, Rome R, Funder JW, Fortune D, Pepperell RJ 1982 Cytoplasmic steroid receptors in ovarian rumours. Br J Obstet Gynaecol 89:754-749
305. 303. Creasman WT, Sasso RA, Weed Jr JC, McCarty Jr KS 1981 Ovarian carcinoma: histologic and clinical correlation of cytoplasmic estrogen and progesterone binding. Gynecol Oncol 12:319-327
306. 304. Hempling RE, Piver MS, Eltabbakh GH, Recio FO 1998 Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. Am J Clin Oncol 21:447-451
307. 305. Masood S, Heitmann J, Nuss RC, Benrubi GI 1989 Clinical correlation of hormone receptor status in epithelial ovarian cancer. Gynecol Oncol 34:57-60
308. 306. Kuhnel R, Delemarre JF, Rao BR, Stolk JG 1987 Correlation of multiple steroid receptors with histological type and grade in human ovarian cancer. Int J Gynecol Pathol 6:248-256
309. 307. Slotman BJ, Kuhnel R, Rao BR, Dijkhuizen GH, De Graaff J, Stolk JG 1989 Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival. Gynecol Oncol 33: 76-81
310. 308. Slotman BJ, Rao BR 1988 Ovarian cancer. Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy, and endocrine therapy. Anticancer Res 8:417-434
311. 309. Freedman RS, Saul PB, Edwards CL, Jolles CJ, Gershenson DM, Jones LA, Atkinson EN, Dana WJ 1986 Ethinyl estradiol, medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: a phase II study. Cancer Treat Rep 70:369-373
312. 310. Jakobsen A, Bertelsen K, Sell A 1987 Cyclic hormonal treatment in ovarian cancer. A phase-II trial. Eur J Cancer Clin Oncol 23: 915-916
313. 311. Schwartz PE, Keating G, MacLusky N, Naftolin F, Eisenfeld A 1982 Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol 59:583-588
314. 312. Shirey DR, Kavanagh Jr JJ, Gershenson DM, Freedman RS, Copeland LJ, Jones LA 1985 Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol 66:575-578
315. 313. Slevin ML, Harvey VJ, Osborne RJ, Shepherd JH, Williams CJ, Mead GM 1986 A phase II study of tamoxifen in ovarian cancer. Eur J Cancer Clin Oncol 22:309-312
316. 314. Weiner SA, Alberts DS, Surwit EA, Davis J, Grosso D 1987 Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol 27:208-213
317. 315. Slotman BJ, Rao BR 1989 Response to inhibition of androgen action of human ovarian cancer cells in vitro. Cancer Lett 45:213-220
318. 316. Simpson BJB, Langdon SP, Rabiasz GJ, Macleod KG, Hirst GL, Bartlett JMS, Crew AJ, Hawkins RA, Madneira-Perez PP, Smyth JF, Miller WR 1998 Estrogen regulation of transforming growth factor-α in ovarian cancer. J Steroid Biochem Mol Biol 64:137-145
319. 317. Krywicki RF, Figueroa JA, Jackson JG, Kozelsky TW, Shimasaki S, Von Hoff DD, Yee D 1993 Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen. Eur J Cancer 29:2015-2019
320. 318. Nash JD, Ozols RF, Smyth JF, Hamilton TC 1989 Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro. Obstet Gynecol 73:1009-1016
321. 319. Mills GB, Hashimoto S, Hurteau J, Schmandt R, Campbell S, May C, Hill M, Shaw P, Buckman R, Hogg D 1992 Regulation of Growth of Human Ovarian Cancer Cells. In: Sharp F, Mason WP, Creaseman W (eds) Ovarian Cancer. Biology, Diagnosis and Management. Chapman & Hall, London, vol 2:127-143
322. 320. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Maerkman M, Casey G 1998 Lysophosphatidic acid as a potential biomarker in ovarian and other gynecological tumors. J Am Med Assoc 280:719-723
323. 321. Di Blasio AM, Cremonesi L, Vigano P, Ferrari M, Gospodarowicz D, Vignali M, Jaffe RB 1993 Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms. Am J Obstet Gynecol 169:1517-1523
324. 322. Roberts AB, Sporn MB 1990 The transforming growth factor-[betas]. In: Sporn MB, Roberts AB (eds) Peptide Growth Factors and Their Receptors. Springer, Heidelberg, pp 419-472
325. 323. Massague J, Cheifetz S, Laiho M, Ralph DA, Weis FMB, Zentella A 1992 Transforming growth factor-β. Cancer Surv 12:81-103
326. 324. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J 1994 Mechanism of activation of the TGF-β receptor. Nature 370:341-347
327. 325. Massague J 1992 Receptors for the TGF-β family. Cell 69:1067-1070
328. 326. Bassing CH, Yingling JM, Howe DJ, Wang T, He WW, Gustafson ML, Shah P, Donahoe PK, Wang X-F 1994 A transforming growth factor β type I receptor that signals to activate gene expression. Science 263:87-89
329. 327. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J 1994 Mechanism of activation of the TGF-β receptor. Nature 370:341-347
330. 328. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang X-F, Massague J 1992 TGFβ signals through a heteromeric protein kinase receptor complex. Cell 71:1003-1014
331. 329. Lopez-Casilla F, Cheifetz S, Doody J, Andres JL, Lane WS, Massague J 1991 Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system. Cell 67:758-795
332. 330. Wang X-F, Lin HY, Ng-Eaton E, Downward J, Lodish HF, Weinberg RA 1991 Expression cloning and characterization of the TGF-β type III receptor. Cell 67:797-805
333. 331. Carcamo J, Zentella A, Massague J 1995 Disruption of transforming growth factor β signaling by a mutation that prevents transphosphorylation within the receptor complex. Mol Cell Biol. 15:1573-1581
334. 332. Bartlett JM, Landon SP, Scott WN, Love SB, Miller EP, Katsaros D, Smyth JF, Miller WR 1997 Transforming growth factor-β isoform expression in human ovarian rumors. Eur J Cancer 33:2397-2403
335. 333. Bartlett JMS, Rabiasz GJ, Scott WN, Langdon SP, Smyth JF, Miller WR 1992 Transforming growth factor-β mRNA expression and growth control of human ovarian carcinoma cells. Br J Cancer 65:655-660
336. 334. Marth C, Lang T, Koza A, Mayer I, Daxenbichler G 1990 Transforming growth factor-beta and ovarian carcinoma cells: regulation of proliferation and surface antigen expression. Cancer Lett 51: 221-225
337. 335. Hurteau J, Rodriguez GC, Whitaker RS, Shah S, Mills G, Bast Jr RC, Berchuck A 1994 Transforming growth factor-β inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 74:93-99
338. 336. Daniels AM, McPherson JM, Daniels JR, Fiez KA 1989 Unusual antiproliferative effects of transforming growth factors-β1 and β2 against primary cells from human tumors. Biotherapy 1:133-137
339. 337. Berchuck A, Olt GJ, Everitt L, Soisson AP, Bast Jr RC, Boyer CM 1990 The role of peptide growth factors in epithelial ovarian cancer. Obstet Gynecol 75:255-62
340. 338. Kalkhoven E, Roelen BAJ, de Winter JF, Mummery CL, van den Eijnden-van Raaij AJM, van der Saag PT, van der Burg B 1995 Resistance to transforming growth factor β and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ 6:1151-1161
341. 339. Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, George D 1994 Loss of receptors for transforming growth factor β in human T-cell malignancies. Proc Natl Acad Sci USA 91:6002-6006
342. 340. Park K, Kim S-J, Ban Y-J, Park J-G, Kim NK, Roberts BA, Sporn MB 1994 Genetic changes in the transforming growth factor β (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β. Proc Natl Acad Sci USA 91:8772-8776
343. 341. Inagaki M, Moustakas A, Lin HY, Lodish HF, Carr BI 1993 Growth inhibition by transforming growth factor β (TGF-β) type I is restored in TGF-β-resistant hepatoma cells after expression of TGF-β receptor type II cDNA. Proc Natl Acad Sci USA 90:5359-5363
344. 342. Pietenpol JA, Stein RW, Moran E, Yaciuk P, Schlegel R, Lyons RM, Pittelkow R, Munger K, Howley PM, Moses HL1990 TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 61:777-785
345. 343. Fynan TM, Reiss M 1993 Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncol 4:493-540
346. 344. Reiss M, Velluci VF, Zhou Z 1993 Mutant p53 rumor suppressor gene causes resistance to transforming growth factor-β1 in murine keratinocytes. Cancer Res 53:899-904
347. 345. Jacobs IJ, Kohler M, Wiseman R, Marks J, Whitaker R, Kerns BA, Humphrey P, Berchuck A, Ponder BA, Bast Jr RC 1992 Clonal origin of epithelial ovarian cancer: analysis by loss of heterozygosity, p53 mutation and X-chromosome inaetivation. J Natl Cancer Inst 84:1793-1798
348. 346. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast Jr RC, Berchuck A 1993 Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85:1513-1519
349. 347. Selvakumuran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B, Liebermann D 1994 Immediate early up-regulation of bax expression by p53 but not TGF-β-1: a paradigm for distinct apoptotic pathways. Oncogene 9:1791-1798
350. 348. Ullrich Schlessinger J 1990 Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212
351. 349. Bauknecht T, Runge M, Shceall M, Pfleiderer A 1988 Occurrence of epidermal growth factor receptors in human adrenal tumors and their prognostic value in advanced ovarian carcinomas. Gynecol Oncol 29:147-157
352. 350. Bauknecht T, Angel P, Kohler M, Kommoss F, Birmelin G, Pfleiderer A, Wagner E 1993 Gene structure and expression analysis of the epidermal growth factor receptor, transforming growth factor alpha, myc, jun and metallothionein in human ovarian carcinomas: classification of malignant phenotypes. Cancer 71:419-429
353. 351. Battagila F, Scambia G, Beneditti Panici P, Baiocchi G, Perroni L, lacobelli S, Nancuros S 1989 Epidermal growth factor expression in gynecological malignancies. Gynecol Obstet Invest 27:42-44
354. 352. Morishige K, Kurachi H, Amemiya K, Fujita Y, Yamamoto T, Miyake A, Tanizawa O 1991 Evidence for the involvement of transforming growth factor-α and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. Cancer Res 51:5322-5328
355. 353. Henzen-Logmans SC, Berns EMJJ, Klijn JGM, van der Burg ME, Foekens JA 1992 Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay. Br J Cancer 66:1015-1021
356. 354. Berns EMJJ, Klijn JGM, Henzen-Logmans SC, Rodenburg CJ, van der Burg ME, Foekens JA 1992 Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer. Int J Cancer 52:218-224
357. 355. Owens OJ, Leake RE 1993 Epidermal growth factor receptor expression in malignant ovary, benign ovarian tumours and normal ovary: a comparison. Int J Cancer 2:321-324
358. 356. Owens OJ, Leaks RE 1992 Growth factor content in normal and benign ovarian tumours. Eur J Obstet Gynecol Reprod Biol 47: 223-228
359. 357. Zhou L, Leung BS 1992 Growth regulation of ovarian cancer cells by epidermal growth factor and transforming growth factor α and β1. Biochim Biophys Acta 1080:130-136
360. 358. Kurachi H, Morishige K, Amemiya K, Adachi H, Hirota K, Miyake A, Tanizawa O 1991 Importance of transforming growth factor α/epidermal growth factor receptor autocrine growth mechanism in ovarian cancer cell line in vitro. Cancer Res 51:5956-5959
361. 359. Crew JA, Langdon SP, Miller EP, Miller WR 1992 Mitogenic effects of epidermal growth factor and transforming growth factor-α on EGF-receptor positive human ovarian carcinoma cell lines. Eur J Cancer 28:337-341
362. 360. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF 1989 Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244:707-712
363. 361. Haldane JS, Hird V, Hughes CM, Gullick WJ 1990 c-erbB-2 Oncogene expression in ovarian cancer. J Pathol 162:231-237
364. 362. Hung M-C, Zhang X, Van D-H, Zhang HZ, He GP, Zhang TQ, Shi DR 1992 Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. Cancer Lett 61:95-103
365. 363. Kraus MH, Using W, Miki T, Popescu NC, Arronson SA 1989 Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86:9193-9197
366. 364. Plowman GD, Culouscu JM, Whirney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M 1993 Ligand-specific activation of HER4/p180etbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90:1746-1750
367. 365. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K 1986 Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230-234
368. 366. Simpson BJB, Phillips HA, Lessells AM, Langdon SP, Miller WR 1995 c-erbB growth-factor-receptor proteins in ovarian tumours. Int J Cancer 64:202-206
369. 367. Goldman R, Levy RB, Peles E, Yarden Y 1990 Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. J Biochem 29:11024-11028
370. 368. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway III KL 1994 Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 269:14661-14665
371. 369. Plowman GD, Green JM, Culouscou JM, Carlton GW, Rothwell VM, Buckely S 1993 Heregulin induce tyrosin phosphorylation of HER4/p180erbB4, Nature 366:473-475
372. 370. Peles E, Ben-levy R, Tzahar E, Liu N, Wen D, Yarden Y 1993 Cell-type specific interaction of Neu differentiation factor (NDF/ heregulin) with Neu/HER-2 suggest complex ligand-receptor relationships. EMBO J 12:961-971
373. 371. Wiechen Kai, Karaaslan S, Dietel M 1999 Involvement of the c-erbB-2 oncogene product in the EGF-induced cell motility of SK-OV-3 ovarian cancer cells. Int J Cancer 83:409-414
374. 372. MacCawley LJ, O'Brien P, Hudson LG 1998 Epidermal growth factor (EGF)- and scatter factor/hepatocyte growth factor (SF/HGF)-mediated keratinocyte migration is coincident with induction of matrix metalloproteinase (MMP)-9. J Cell Physiol 176: 255-265
375. 373. Christen RD, Hom DK, Porter DC, Andrews PA, Macleod CL, Hafestrm L, Howell SB 1990 Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest 86:1632-1640
376. 374. Stack MS, Ellerbroek SM, Fishman DA 1998 The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. Int J Oncol 12:569-576
377. 375. Young TN, Rodriguez GC, Rinehart AR, Bast Jr RC, Pizzo SV, Stack MS 1996 Characterization of gelatinase linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 62:89-99
378. 376. van der Burg Mel henzen-Logmans SC, Foekens JA, Berns EMJJ, Rodenburg CJ, van Putten WLJ, Klijn JGM 1993 The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. Eur J Cancer 29:1951-1957
379. 377. Harris AL, Nicholson S, Stainsbury JR, Farndon JR, Wright C 1989 Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 34:123-131
380. 378. Bartlett JMS, Langdon SP, Simpson BJB, Stewart M, Katsaros D, Sismondi P, Love S, Scott WN, Williams ARW, Lessells AM, Macleod KG, Smyth JF, Miller WR 1996 The prognostic value of epidermal growth facto receptor mRNA expression in primary ovarian cancer. Br J Cancer 73:301-306
381. 379. Chien CH, Huang CC, Lin YH, Snen J, Chow SN 1997 Detection of serum transforming growth factor-α in patients of primary epithelial ovarian cancers by enzyme immunoassay. Gynecol Oncol 66:405-410
382. 380. Fan Z, Mendelsohn J 1998 Therapeutic application of anti-growth factor receptor antibodies. Curr Opin Oncol 10:67-73
383. 381. Mendelsohn J 1990 The epidermal growth factor receptors as a target therapy with antireceptor monoclonal antibodies. Semin Cancer Biol 1:339-344
384. 382. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L 1996 Phase II study of weekly intravenous recombinant humaized ant-p185 HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744
385. 383. Ye Dingwei, Mendelsohn J, Fan Z 1998 Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18:731-738
386. 384. Simpson BJB, Bartlett JMS, Macleod KG, Rabiasz G, Miller EP, Rae AL, Gordge P, Leake RE, Miller WR 1999 Inhibition of transforming growth factor α (TGF-α)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868. Br J Cancer 79:1098-1103
387. 385. Wiechen K, Dietel M 1995 c-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of P185c-erbB-2-overexpressing ovarian carcinoma cells. Int J Cancer 63:604-608
388. 386. Wu L, Wu A, Jiang K 1996 Effect of antisense c-erbB2 on biologic behaviour and chemotherapeutic drug sensitivity in human ovarian cancer cells [in Chinese]. Chung Hua Fu Chan Ko Tsa Chih 31:169-172
389. 387. Deshane J, Loechel F, Conry RM, Siegal GP, King CR, Curiel DT 1994 Intracellular single-chain antibody directed against erbB down-regulates cell surface erbB2 and exhibits a selective antiproliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther 1:332-337
390. 388. Rosen EM, Nigam SK, Goldberg ID 1994 Scatter factor and the c-Met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol 127:225-234
391. 389. Parrott JA, Skinner MK 1998 Developmental and hormonal regulation of hepatocyte growth factor expression and action in the bovine ovarian follicle. Biol Reprod 59:553-560
392. 390. Boccaccio C, Gaudino G, Gambarotta G, Galimi F, Comoglio PM 1994 Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed early response to HGF. J Biol Chem 269:12846-12851
393. 391. Sowter HM, Corps AN, Smith SK 1999 Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells. Int J Cancer 83:476-480
394. 392. Corps AN, Sowter HM, Smith SK 1997 Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met. Int J Cancer 73:151-155
395. 393. Ueoka Y, Kato K, Kuriaki Y, Horiuchi S, Terao Y, Nishida J, Ueno H, Wake N 2000 Hepatocyte growth factor mediates motility and invasiveness of ovarian carcinomas vis Ras-mediated pathway. Br J Cancer 82:891-899
396. 394. Daughaday WH 1990 The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology 127:1-4
397. 395. Cullen KJ, Yee D, Rosenfeld RG 1991 Insulin-like growth factors in human malignancy. Cancer Invest 9:443-454
398. 396. LeRoith D, Baserga R, Helman L, Roberts Jr CT 1995 Insulin-like growth factors and cancer. Ann Intern Med 122:54-59
399. 397. Yee D, Morales FR, Hamilton TC, Von Hoff DD 1991 Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res 51:5107-5112
400. 398. Beck EP, Russo P, Gliozzo B, Jaeger W, Papa V, Wildt L, Pezzino V, Lang N 1994 Identification of insulin and insulin-like growth factor I (IGF I) receptors in ovarian cancer tissue. Gynecol Oncol 53:196-201
401. 399. van Dam PA, Vergote IB, Lowe DG, Watson JV, van Damme P, van der Auwera JC, Shepherd JH 1994 Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol 47:914-919
402. 400. Karasik A, Menczer J, Pariente C, Kanety H 1994 Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 78:271-276
403. 401. Conover CA, Hartmann LC, Bradley S, Stalboerger P, Klee GG, Kalli KR, Jenkins RB 1998 Biological characterization of human epithelial ovarian carcinoma cells in primary culture; the insulin-like growth factor system. Exp Cell Res 238:439-449
404. 402. Yun K, Fukumoto M, Jinno Y 1996 Monoallelic expression of the insulin-like growth factor-2 gene in ovarian cancer. Am J Pathol 148:1081-1087
405. 403. Coppola D, Saunders B, Fu L, Mao W, Nicosia SV 1999 The insulin-like growth factor 1 receptor induces transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas-receptor expression. Cancer Res 59:3264-3270
406. 404. Kanety H, Kattan M, Goldberg I, Kopolovic J, Ravia J, Menczer J, Karasik A 1996 Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br J Cancer 73:1069-1073
407. 405. Flyvbjerg A, Mogensen O, Mogensen B, Nielsen OS 1997 Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab 82:2308-2313
408. 406. Krywicki RF, Figueroa JA, Jackson JG, Kozelsky TW, Shimasaki S, Von Hoff DD, Yee D 1993 Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen. Eur J Cancer 29:2015-2019
409. 407. Muller M, Dietel M, Turzynski A, Wiechen K 1998 Antisense phosphorothioate oligodeoxynucleotide down-regulation of the insulin-like growth factor-I receptor in ovarian cancer cells. Int J Cancer 77:567-571
410. 408. Resnicoff M, Ambrose D, Coppola D, Rubin R 1993 Insulin-like growth factor 1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab Invest 69:756-760
411. 409. Yin DL, Pu L, Fei G 1998 Antisense oligonucleotide to insulin-like growth factor II induces apoptosis in human ovarian cancer AO cell line. Cell Res 8:159-165
412. 410. Berse B, Brown L, van de Water L, Dvorak H, Senger D 1992 Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophases, and tumors. Mol Biol Cell 3:211-220
413. 411. Senge D, Peruzzi C, Feder J, Dvorak H 1986 A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46:5629-5632
414. 412. Phillips HS, Hains J, Leung DW, Ferrara N 1990 Vascular endothelial growth factor is expressed in the rat corpus luteum. Endocrinology 127:956-967
415. 413. Connolly DT, Olander JV, Heuvelman DM, Nelson R, Monsell R, Siegel NR, Haymore BL, Leimgruber RM, Feder J 1989 Human vascular permeability factor: isolation from U937 cells. J Biol Chem 264:20017-20024
416. 414. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi BZ 1994 Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 5:89-97
417. 415. Yeo KT, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, Zhou Y, Masse EM, Senger DR, Dvorak HF 1993 Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human rumor and inflammatory effusions. Cancer Res 53:2912-2918
418. 416. Olson TA, Mohanraj D, Carson LF, Ramakrishman S 1994 Vascular permeability factor gene expression in normal and neoplastic ovaries. Cancer Res 54:276-280.
419. 417. Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, Brown LF 1996 Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptor in ovarian borderline and malignant neoplasms. Lab Invest 74: 1105-1115
420. 418. Boocock CA, Charcock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Simth SK 1995 Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87:506-516
421. 419. Mesiano S, Ferrara N, Jaffe RB 1998 Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153:1249-1256
422. 420. Yamaoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, Sakahara H, Mori T 1997 Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76:1221-1227
423. 421. Hartenbach EM, Oison TA, Goswitz JJ, Mohanraj D, Twiggs LB, Carson LF, Ramakrishnan S 1997 Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 121:169-175
424. 422. Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, Sakahara H, Mori T 1997 Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76:1221-1227
425. 423. Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, Kainz C 1998 Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 92:360-2363
426. 424. Oehler MK, Caffier H 1999 Diagnostic value of serum VEGF in women with ovarian tumors. Anticancer Res 19:2519-2522
427. 425. Gadducci A, Ferdeghini M, Fanucchi A, Annicchiarico C, Ciampi B, Prontera C, Genazzani AR 1999 Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anti-cancer Res 19:1401-1405
428. 426. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K 1993 Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53:4550-4554
429. 427. Fujimoto J, Ichigo S, Sakaguchi H, Hirose R, Tamaya T 1998 Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in ovarian cancers. Cancer Lett 126:83-88
430. 428. Reynolds K, Farzaneh F, Collins WP, Campbell S, Bourne TH, Lawton F, Moghaddam A, Harris AL, Bicknell R 1994 Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst 86:1234-1238
431. 429. Crickard K, Gross JL, Crickard U, Yoonessi M, Lele S, Herblin WF, Eidsvoog K 1994 Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol Oncol 55:277-284
432. 430. Di Blasio AM, Carniti C, Vigano P, Vignali M 1995 Basic fibroblast growth factor and ovarian cancer. J Steroid Biochem Mol Biol 53:375-379
433. 431. Fujimoto J, Ichigo S, Hon M, Hirose R, Sakaguchi H, Tamaya T 1997 Expression of basic fibroblast growth factor and its mRNA in advanced ovarian cancers. Eur J Gynaecol Oncol 18:349-352
434. 432. Obermair A, Speiser P, Reisenberger K, Ullrich R, Czerwenka K, Kaider A, Zeillinger R, Miksche M 1998 Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. Cancer Lett 130:69-76
435. 433. Kacinski BM, Carter D, Mittal K, Yee LD, Scata KA, Donofrio L, Chambers SK, Wang KI, Yang-Fent T, Rohrschneider LR, Roswell VM 1990 Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. Am J Pathol 137:135-147
436. 434. Cimoli G, Russo P, Billi G, Mariani GL, Rovini E, Venrurini M 1991 Human granulocyte-macrophage colony-stimulating factor is a growth factor active on human ovarian cancer cells. Jpn J Can Res 82:1196-1198
437. 435. Malik S, Balkwill F 1991 Epithelial ovarian cancer: a cytokine propelled disease? [Editorial] Br J Cancer 64:617-620
438. 436. Scambia G, Testa U, Panici PB, Marrucci R, Foti E, Petrini M, Amoroso M, Masciullo V, Peschle C, Mancuso S 1994 Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer 57:318-323
439. 437. Balkwill FR 1992 Tumour necrosis factor and cancer. Prog Growth Factor Res 4:121-137
440. 438. Bast Jr RC, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M, Berchuck A 1993 Cell growth regulation in epithelial ovarian cancer. Cancer 71:1597-1601
441. 439. Kacinski BM, Carter D, Mittal K, Kohorn EI, Bloodgood RS, Donahue J, Donofrio L, Edwards R, Schwartz PE, Chambers JT, Chambers SK 1988 High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. Int J Radiat Oncol Biol Phys 15:823-829
442. 440. Tang R, Beuvon F, Ojeda M, Mosseri V, Pouillart P, Scholl S 1992 M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes? J Cell Biochem 50:350-356
443. 441. Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O 1990 Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 50:6959-6965
444. 442. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O 1991 Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 164:1038-1043
445. 443. Watson JM, Berek JS, Martinez-Maza O 1993 Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecol Oncol 49:8-15
446. 444. Mobus VJ, Asphal W, Knapstein PG, Kreienberg R 1993 Effects of Interferon gamma on the proliferation and modulation of cell-surface structures of human ovarian carcinoma cell lines. J Cancer Res Clin Oncol 120:27-34
447. 445. Mishra S, Hamburger AW 1994 Interferon γ-induced reduction in erbB-2 tyrosyl phosphorylation in human ovarian carcinoma cells. Int J Cancer 58:538-542
448. 446. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, Hurteau J, Casey G, Goodbody A, Mellors A, Holub BJ, Mills GB 1995 Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1:1223-1232
449. 447. Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, Jaffe RB, Wiener JR, Erickson JR, Mills GB 2000 Lysophospholipid growth factors in the initiation progression metastases and management of ovarian cancer. Ann NY Acad Sci 905:188-208
450. 448. Westermann AM, Havik E, Postma FR, Beijnen JH, Dalesio O, Moolenaar WH, Rodenhuis S 1998 Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 9:437-442